Overview

• The health department ordered government hospitals to stop use, distribution and procurement of the named batches immediately and to isolate any existing stock.
• The directive lists specific products and batches, including Normal Saline, Dextrose 5%, Ciprofloxacin 200 mg, DNS 0.9%, N/2 + Dextrose 5%, and Bupivacaine HCL with Dextrose, with expiries running through 2026–2028.
• The suspended batches were manufactured by Swaroop Pharmaceuticals, Otsuka Pharmaceutical India and Health Biotech, according to the official memo.
• A committee under the Punjab Health Systems Corporation was tasked to evaluate the suspected adverse drug reactions, while samples from the flagged batches were dispatched for lab analysis.
• Hospitals were warned of departmental action for non‑compliance, as the suspension follows a recent Coldrif syrup ban and earlier IV‑fluid recalls that have sharpened scrutiny of procurement and quality controls.